Syros Pharmaceuticals, Inc. SYRS

SYRS Company Overview

Syros Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for hematologic malignancies and other cancers with high unmet medical need. The company operates within the biotechnology and oncology drug development industries, with its core activities centered on precision medicine, gene regulation science, and molecularly targeted therapeutics. Syros has historically concentrated on identifying and advancing therapies designed to control gene expression and address genetically defined patient populations.

The company’s principal revenue drivers have historically consisted of collaboration revenue, licensing arrangements, and external funding associated with research partnerships, rather than commercial product sales, as it remains primarily a development-stage enterprise. Syros’ lead development programs have included tamibarotene, an oral selective retinoic acid receptor alpha agonist evaluated in acute myeloid leukemia and myelodysplastic syndromes, and SY-2101, an oral arsenic trioxide formulation. Founded in 2011 and headquartered in Cambridge, Massachusetts, the company evolved from an epigenetics and gene-control research platform into a focused oncology therapeutics developer emphasizing biomarker-driven clinical programs.